Related Experiment Video
Updated: Mar 11, 2026
06:51
Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
18.8K
PLK1, A Potential Target for Cancer Therapy
Zhixian Liu1, Qingrong Sun2, Xiaosheng Wang1
1Department of Basic Medicine, School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University, Nanjing 211198, China.
Translational Oncology
|November 27, 2016
Summary
Polo-like kinase 1 (PLK1) is crucial for cell division and often overexpressed in cancers. Inhibiting PLK1 shows promise as a cancer therapy by disrupting mitosis and causing cancer cell death.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- Polo-like kinase 1 (PLK1) is vital for mitosis regulation.
- PLK1 dysfunction is linked to cancer development and progression.
- Overexpression of PLK1 correlates with poor prognosis in various cancers.
Purpose of the Study:
- To review PLK1's role in mitosis.
- To analyze PLK1 expression and its prognostic value in cancers.
- To explore PLK1 inhibitors for cancer therapy.
Main Methods:
- Literature review of PLK1's structural and regulatory functions.
- Analysis of PLK1 expression data across diverse cancer types.
- Examination of PLK1 interaction networks and ongoing inhibitor studies.
Main Results:
- PLK1 is essential for accurate cell division.
- PLK1 overexpression is a common feature in many cancers, associated with adverse outcomes.
- Inhibition of PLK1 induces mitotic arrest and cancer cell death.
Conclusions:
- PLK1 is a validated target for cancer therapy.
- Targeting PLK1 offers a promising strategy to combat various malignancies.
- Further research is needed to overcome challenges in developing PLK1-based therapies.
Related Concept Videos
02:57Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
02:34Inhibition of Cdk Activity
6.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.1K
01:22PI3K/mTOR/AKT Signaling Pathway
6.1K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
6.1K
03:03mTOR Signaling and Cancer Progression
5.0K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
5.0K
01:19Interactions Between Signaling Pathways
7.7K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.7K
02:50Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K